Cost-Effectiveness and Cost-Utility Analysis of Sunitinib Versus Sorafenib and Bevacizumab + Interferon-Alfa as First-Line Treatment for Metastatic Renal Cell Carcinoma in Ecuador
Value in Health - United Kingdom
doi 10.1016/j.jval.2013.03.681
Full Text
Open PDFAbstract
Available in full text
Date
May 1, 2013
Authors
Publisher
Elsevier BV